Cannabidivarine (CBDV)
It is higher in plants of Cannabis Indica than in C. Sativa. Isomerize's to Δ9-THCV under acidic conditions, biosynthetic precurcers to this.
Anti-Inflammatory
Beneficial effects on bone formation and fraction healing
Lowers hyperphagia and abdominal obesity
Tetrahydrocannabivarin (THCV)
It has the possibility to inverse agonism both the CB1 and CB2 receptor showing as a beneficial therapy for treating depression and suicidal ideations.
Reduction of seizures
Pain relief
Increases Weight Loss
Lowers hyperphagia and abdominal obesity
Cannabigerol (CBG)
non-psychotropic
Antibacterial Agent
THC and CBD start out as CBG
Inhibit Chronic and Inflammatory pains
Effective anit-hyperalgesic and anti-inflammatory
Cannabidiol (CBD)
Discovered in 1963 by Raphael Mechoulam
Non-psychoactive does not produce the “euphoric” feelings that are accompanied within THC, but still produce an altered state of mind
Ideal for children or people who would prefer a non-psychoactive cannabis experience
Second most abundant cannabinoid found in the hemp plant.
Inhibits obsessive behavior
Low affinity for CB1 or CB2 receptors
Protective against neurodegeneration and mental disorders
Potential benefits in Alzheimer’s disease, multiple sclerosis (MS), Parkinson’s disease and amyotrophic lateral sclerosis
Decreases uptake of adenosine and antioxidants
Immunosuppressive
Anti-Inflammatory
Anti-Anxiety like effects
Lowers blood sugar
When simultaneously administered with THC its effects are more beneficial
Cannabinol (CBN)
When THC is exposed to oxygen and heat an oxidation occurs creating CBN
Can occur over time with older cannabis or cannabis that has past maturing during its growth cycle
Anti-inflammatory
Sedation
Psychoactive
Cannabichromene (CBC)
Non-Psychoactive like THC
Relieves anxiety and stress
Anti-Inflammatory
Pain Reliever
Anti-Viral
Anti-Tumor
Stimulates bone tissue growth
Converts to CBL when exposed to lights
Cannabicyclol (CBL)
Medical properties are unknown
In comparison to other cannabinoids it is concentration is very minuscule to other properties
Possibly inhibits production of hormones that control smooth muscle contractions
Δ9-trans-tetrahydrocannabinol (Δ9-THC)
Main psychoactive compound in Cannabis Sativa isolated in Mechoulam’s Laboratory in 1964
binds to the CB2 receptor.
Immunosuppressive
Anti-inflammatory
Dampening the immune system without psychoactive effects beneficial to possibly improve autoimmune diseases and outcomes for graft rejection.
Possibly induces dependency and tolerance
Pain Reduction
Anti-Nausea
Treatment of ADHD
Δ8-trans-tetrahydrocannabinol (Δ8-THC)
Less psychotropic comparatively to Δ9-THC
Binds to the CB1/CB2 receptors
Increases appetite
Analgesic
Neuroprotector
(Δ9-THC can be modified into D8)
anti-anxiety
Acids
Cannabidiolic Acid (CBDA)
Converts to CBD within application of heat.
More potent than CBD within
Non-psychoactive “high” like THC
Anti-Anxiety like effects
Surpreses locomotive effects
Reduces Nausea and Vomiting
Lowers hyperphagia and abdominal obesity
Increases appetite for palatable food
Cannabigerolic Acid (CBGA)
When CBGA is broken down it is coverted into THCA or CBDA
Can be manipulated to produce higher CBG within plants through cross-needing
Lowers hyperphagia and abdominal obesity
Δ9-tetrahydrocannabinolic acid-A (THCAA)
converts to THC within application of heat.
More potent than THC
Reduces Nausea
FDA Disclaimer
The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from healthcare practitioners. Please consult your healthcare professional about potential interactions or other possible complications before using any product. The Federal Food, Drug, and Cosmetic Act require this notice.
Work Cited:
Deiana, S., Watanabe, A., Yamasaki, Y. et al. Psychopharmacology (2012) 219: 859. https://doi- org.proxy.lib.pdx.edu/10.1007/s00213-011-2415-0
Eisenstein, Toby K., and Joseph J. Meissler. “Effects of Cannabinoids on T-Cell Function and Resistance to Infection.” Journal of Neuroimmune Pharmacology, vol. 10, no. 2, 2015, pp. 204–216., doi:10.1007/s11481-015-9603-3.11 Cannabinoids that are presented in most varieties of cannabis.
Gul, Waseem, et al. “Determination of 11 Cannabinoids in Biomass and Extracts of Different Varieties of Cannabis Using High-Performance Liquid Chromatography.” Journal of AOAC International, vol. 98, no. 6, Aug. 2015, pp. 1523–1528., doi:10.5740/jaoacint. 15-095.
Interactive, Devise. “Global Leader in Cannabis Testing and Analytics.” Steep Hill Labs, www.steephill.com/science/cannabinoids.
Journal of Neuroimmune Pharmacology, 2015, Vol.10(2), pp.204-216[Peer Reviewed Journal]
Effects of Cannabinoids on T-cell Function and Resistance to Infection
Petrocellis, Luciano De, et al. “Effects of Cannabinoids and Cannabinoid‐Enriched Cannabis Extracts on TRP Channels and Endocannabinoid Metabolic Enzymes.” British Journal of Pharmacology, Blackwell Publishing Ltd, 12 July 2011, onlinelibrary.wiley.com/doi/ 10.1111/j.1476-5381.2010.01166.x/full.
Rock, Erin M., et al. “A Comparison of Cannabidiolic Acid with Other Treatments for Anticipatory Nausea Using a Rat Model of Contextually Elicited Conditioned Gaping.” Psychopharmacology, vol. 231, no. 16, May 2014, pp. 3207–3215., doi:10.1007/ s00213-014-3498-1.
Zuardi, A.W., Hallak, J.E.C. & Crippa, J.A.S. Psychopharmacology (2012) 219: 247. https://doi- org.proxy.lib.pdx.edu/10.1007/s00213-011-2495-x